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Background
Medulloblastoma is the most common malignant brain
tumor in childhood. It arises in the cerebellum or
medulla/brainstem, and shows tremendous biological and
clinical heterogeneity. Despite advances in treatment for
medulloblastoma over the past few decades, approximately
40% of children who develop this aggressively growing
malignancy will experience tumor recurrence, and 30%
will die from the disease. Importantly, recent work has
shown that medulloblastoma is not a single disease, but
comprises at least four distinct molecular subgroups [1].
WNT tumors, displaying activated wingless pathway sig-
naling, carry a favorable prognosis. SHH tumors show
hedgehog pathway activation, and have an intermediate
prognosis. Group 3 and 4 tumors are molecularly less well
characterized, and present the greatest clinical challenges.
The full repertoire of genetic events driving this distinc-
tion, however, remains unclear.
We have recently described an integrative deep-sequen-
cing analysis of 125 tumor-normal pairs, conducted as
part of the International Cancer Genome Consortium
(ICGC) PedBrain Tumor Project [2]. Here, we focus on
genome-wide somatic mutations in medulloblastoma, how
they are distributed throughout the genome, how they are
correlated with patient age at diagnosis, the influence of
subgroup affiliation on mutation rate, and how the muta-
tion allele frequencies can be utilized to predict ploidy and
infer temporal evolution of the tumor.
Materials and methods
We sequenced the complete genomes of 39 primary
medulloblastoma and matched normal DNAs from the
same individuals, aged from 0 to 17 years, using Illumina
technology. Cancer and normal DNAs were sequenced to
an average of 35-fold coverage and analyzed to identify
somatic base substitutions, small insertions, deletions, and
copy number changes.
Results
Tetraploidy was identified as a frequent event in clinically
challenging group 3 and 4 tumors. The extremely low
fraction of mutations at approximately 50% allele fre-
quency indicates that genome duplication occurred very
early during tumorigenesis. For non-tetraploid tumors, a
clear positive correlation of patients’ age and mutation
number was observed. The average somatic mutation
rate was 0.52 per megabase (Mb), with an average of 10.3
non-synonymous coding single nucleotide variants,
amounts considerably lower than in deep-sequenced
adult malignancies. SHH tumors harboring TP53 muta-
tions showed a significantly higher mutation rate both
genome wide and for non-synonymous changes. Interest-
ingly, the WNT subgroup, which typically shows a good
prognosis, had the next highest mutation rate. Several
recurrent coding mutations were identified, both in
known medulloblastoma-related genes and in genes not
previously linked to this tumor, often in subgroup-speci-
fic patterns. Chromatin modifiers were frequently altered
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Conclusions
Next-generation sequencing of this large cohort has pro-
vided a detailed insight into new mechanisms contributing
to medulloblastoma tumorigenesis, enhancing our under-
standing of the genomic complexity and heterogeneity
underlying medulloblastoma, and providing several poten-
tial targets for new therapeutics.
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